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Abstract
A unique two-stage cyclone bioaerosol sampler has been developed at NIOSH that can separate 
aerosols into three size fractions. The ability of this sampler to collect infectious airborne viruses 
from a calm-air chamber loaded with influenza A virus was tested. The sampler’s efficiency at 
collecting aerosolized viral particles from a calm-air chamber is essentially the same as that from 
the high performance SKC BioSampler that collects un-fractionated particles directly into a liquid 
media (2.4 × 104 total viral particles per liter of sampled air (TVP/L) versus 2.6 × 104 TVP/L, 
respectively, after 15 min) and the efficiency is relatively constant over collection times of 15, 30 
and 60 min. Approximately 34% of the aerosolized infectious virus collected after 15 min with the 
NIOSH bioaerosol sampler remained infectious, and infectious virus was found in all three size 
fractions. After 60 min of sampling, the infectious virus/liter air found in the NIOSH bioaerosol 
sampler was 15% of that found in the SKC BioSampler. This preservation of infectivity by the 
NIOSH bioaerosol sampler was maintained even when the initial infectivity prior to aerosolization 
was as low as 0.06%. The utility of the NIOSH bioaerosol sampler was further extended by 
incorporating an enhanced infectivity detection methodology developed in our laboratory, the viral 
replication assay, which amplified the infectious virus making it more readily detectable.
Introduction
Concern regarding human exposure to bioaerosols has led to the development of a variety of 
air sampling devices. However, research addressing the efficacy of current samplers to detect 
infectious airborne viruses is sparse and points to the need for a more efficient sampler.1 A 
two-stage cyclone bioaerosol sampler has been developed by the National Institute for 
Occupational Safety and Health (NIOSH).2 The NIOSH bioaerosol sampler is unique in that 
it size-fractionates aerosols and collects them in disposable centrifuge tubes, facilitating 
direct sample processing. As ambient air is drawn into an inlet at 3.5 L min−1, the first stage 
of the NIOSH bioaerosol sampler deposits aerosol particles that are >4 µm on the wall of a 
15 ml centrifuge tube. In the second stage, 1 to 4 µm particles are deposited on the wall of a 
1.5 ml microcentrifuge tube, and particles that are <1 µm are collected on a 37 mm 
polytetrafluoroethylene (PTFE) filter. The first stage of the sampler collects the non-
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respirable size fraction, while the second stage and filter collect the respirable fraction.3 The 
sampler is lightweight and can be used either as a stationary sampler (such as on a tripod in 
a hospital room), or as a personal breathing zone air sampler that can be worn on the 
clothing of workers in occupational environments.
In a previous study, collection of aerosolized influenza virus in a calm-air settling chamber 
was characterized using an earlier version of the NIOSH bioaerosol sampler.4 Analysis by 
quantitative polymerase chain reaction (qPCR) demonstrated that the sampler effectively 
captured and separated viral-laden particles based on their aerodynamic size. In later studies, 
improved NIOSH bioaerosol samplers (enlargements of the inlet and outlet ports, the 
addition of a 15 ml collection tube, and enlargement of the second stage outlet to reduce 
particle loss due to turbulence) were used as personal and stationary samplers in a hospital 
emergency department and an urgent care clinic during the influenza season. Analysis of the 
collected air samples showed that airborne influenza virus RNA could be found in both 
facilities and that 42–53% of the detectable viral RNA was found in the respirable fraction 
of the aerosol.5,6 Collectively, these studies support the potential for airborne transmission of 
influenza. However, the infectivity of the captured viral aerosols was not addressed.
Numerous reports have shown that the viability of airborne viruses is dependent on the virus 
type, environmental conditions, and on the methods of collection and handling of bioaerosol 
samples.7 For example, the survival of airborne influenza was shown to greatly depend on 
the relative humidity, as well as on ambient air temperature and ultraviolet radiation levels.8 
Collecting influenza, measles, and mumps virus into a viral maintenance fluid instead of 
distilled water resulted in the increased recovery of infectious virus from a bubbling air 
sampler.9 Furthermore, airborne bacteriophages have been shown to retain infectivity longer 
after collection when refrigerated than when stored at room temperature.10
In this study, we have examined the ability of the NIOSH bioaerosol sampler to collect 
infectious airborne influenza A virus and compare it to the SKC BioSampler. An enhanced 
infectivity detection methodology has also been developed in our laboratory11 and this 
method is used to demonstrate the potential utility of the NIOSH bioaerosol sampler for 
collecting real-world environmental samples containing infectious viral particles.
Materials and methods
Cell culture
Madin-Darby canine kidney (MDCK) cells (ATCC CCL-34) were purchased from the 
American Type Culture Collection (ATCC, Manassas, VA). Cells were propagated and 
maintained in 75-cm2 Corning CellBind Surface flasks (Corning Inc. Life Sciences, Lowell, 
MA). Complete growth medium for MDCK cells consisted of Eagle’s minimal essential 
medium (EMEM) (ATCC) supplemented with 10% fetal bovine serum (Hyclone 
Laboratories, Inc, Logan, Utah), 0.4 units/ml penicillin G (Invitrogen, Carlsbad, CA), and 
0.4 µg ml−1 streptomycin (Invitrogen). All incubations were performed at 35 °C in a 
humidified 5% CO2 incubator. Cells were grown until ~90% confluent.
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Virus
Influenza strain A/WS/33 (H1N1, ATCC VR-825, Lot#: 58023547 @1.58 × 108 chicken 
embryo infectious dose 50% endpoint (CEID50)/ml and Lot#: 58772128 @2.8 × 106 
CEID50/ml) was purchased from ATCC.
Bioaerosol samplers
Bioaerosol samplers developed by NIOSH were used to collect influenza virus-containing 
aerosols generated in the laboratory.2,5 For comparison, SKC BioSamplers (SKC Inc, Eighty 
Four, PA) were used. The SKC BioSampler contained 15 ml of Hank’s Balanced Salt 
Solution (HBSS) supplemented with 0.1% bovine serum albumin (BSA) (Sigma-Aldrich, St. 
Louis, MO), 100 units/ml penicillin G and 100 µg ml−1 streptomycin in the 20 ml collection 
vessel.
Calm-air chamber aerosolization and collection of influenza virus
Aerosol collection experiments were conducted in a calm-air settling chamber as shown in 
Fig. 2.12 For each experiment, one vial (1 ml) of influenza A/WS/33 (ATCC) was diluted in 
30 ml or 60 ml of supplemented HBSS. The test aerosol was generated using an Aeroneb 
micropump nebulizer (Aerogen, Galway, Ireland) and combined in a mixing chamber with 
30 L min−1 of filtered conditioned air to achieve a 20% relative humidity (RH). An RH of 
20% was chosen because it is similar to levels measured in a US healthcare facility during 
influenza season.5 The aerosol flowed through a dispersion nozzle into the top center of a 40 
L calm-air chamber and down to the bottom of the chamber where the NIOSH bioaerosol 
samplers and a sample inlet for the SKC BioSamplers were located.
The aerosol concentration and size distribution in the chamber air was measured using a 
Model 3321 Aerodynamic Particle Sizer (APS; TSI, Shoreview, MN) with a 100 : 1 aerosol 
dilutor (Model 3302A, TSI). The APS drew air at 5 L min−1 through a vertical probe at the 
same height as the sampler inlets. From three to five NIOSH bioaerosol samplers were 
positioned inside the calm-air chamber on the bottom plate. The NIOSH bioaerosol samplers 
were connected to Model 224-PCXR4 personal air sampling pumps (SKC, Eighty Four, PA, 
USA) and operated for 15, 30 or 60 min at 3.5 L/min. The flow rates through the NIOSH 
bioaerosol samplers were set before each experiment. The BioSamplers were outside the 
chamber, and drew aerosol samples through a vertical probe in the center of the bottom plate 
of the chamber. Each BioSampler was connected to the sampling port for 15 min and then 
removed, and the next BioSampler was then attached to the port. A ball valve in the 
sampling port was closed while changing BioSamplers. The SKC BioSamplers were 
connected to a central vacuum line and operated at 12.5 L/min.
At the start of each experiment, the Aeroneb nebulizer was operated for 10 min to stabilize 
the aerosol concentration in the chamber. During this time, the APS was in operation and a 
vacuum purge was used to draw the aerosol into the chamber, but the samplers were not on. 
After 10 min, the vacuum purge was turned off and the NIOSH bioaerosol samplers and 
SKC BioSampler were switched on. The nebulizer was continuously operated during each 
experiment to provide a constant loading of aerosols in the chamber at about 0.1 ml of fluid/
min. After the aerosol collection was completed, the nebulizer, the pumps and the vacuum 
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line were turned off. The exterior of the samplers were wiped to remove the deposited 
particles. The NIOSH bioaerosol samplers were disassembled and the collected aerosol 
fractions in each tube and on the filter were suspended in 1 ml of supplemented HBSS.
Viral RNA isolation and cDNA transcription
Viral RNA was isolated directly from aerosol samples using the MagMax™-96 Viral RNA 
Isolation Kit (Applied Biosystems/Ambion, Austin, TX). Briefly, following resuspension of 
collected aerosolized virus from the NIOSH bioaerosol sampler in 1 ml of supplemented 
HBSS, 500 µl of Lysis/Binding Solution Concentrate (Ambion) was added to 500 µl of each 
sample and stored at −20 °C. To process virus collected with the SKC BioSampler, 500 µl of 
Lysis/Binding Solution Concentrate was added directly to 500 µl of each sample and stored 
at −20 °C. Upon thawing, 500 µl of isopropanol was added to each sample to complete the 
Lysis/Binding Solution preparation and viral RNA was extracted according to the 
manufacturer’s instructions. The final eluted total-RNA volume was 32 µl. RNA was 
immediately transcribed into cDNA using High Capacity RNA to cDNA Master Mix 
(Applied Biosystems, Foster City, CA). The final cDNA volume was 40 µl.
Real-time qPCR analysis
To detect influenza virus, real-time qPCR analysis was performed using the following 
matrix1 gene primers13 (corresponding to the 33 amino acids at the n-terminus): Forward 5′-
AGATGAGTCTTCTAACCGAGGTCG-3′, Reverse 5′-
TGCAAAAACATCTTCAAGTCTCTG-3′and probe: 6FAM-TCAGGCCCCCTCAAAGCC-
MGBNFQ. All primers and probes were synthesized by Applied Biosystems and used at a 
final concentration of 0.8 µM and 0.2 µM, respectively. The qPCR (45 cycles) was 
performed with the Applied Biosystems 7500 Fast Real-Time PCR System as follows: 20 s 
at 95 ′C (initial denaturation), 3 s at 95 ′C (amplification), and 30 s at 60 ′C (extension). To 
determine the relative viral genome copy, a standard curve was generated from 10-fold serial 
dilutions of the influenza M1 matrix gene and analyzed concurrently with all qPCR 
reactions. A negative control without template was also included in all real-time PCR 
reactions. All reactions were run in duplicate and averaged.
Viral plaque assay (VPA)
MDCK cells were detached with 0.25% Trypsin-EDTA (Invitrogen), washed and re-
suspended in complete EMEM at a density of 1.0 × 106 cells/ml. Next, 2 ml of the cell 
suspension was added to each well of a 6-well CoStar tissue culture plate (Corning) and 
incubated overnight. Confluent cell monolayers were washed twice with 2 ml of phosphate-
buffered saline (PBS), inoculated with 800 µl of each collected aerosol sample diluted with 
supplemented HBSS, and incubated for 45 min. Inoculated cells were then washed once 
with 2 ml of PBS, overlaid with Dulbecco’s modified Eagle’s medium (DMEM)/F12 
(ATCC) supplemented with 100 units/ml penicillin G, 100 µg ml−1 streptomycin, 2mM L-
glutamine, 0.2% BSA, 10 mM HEPES (Invitrogen), 0.22% sodium bicarbonate (Invitrogen), 
0.01% DEAE-dextran (MP BioMedicals, LLC, Solon, OH), 2 µg ml−1 N-p-tosyl-L-
phenylalanine chloromethyl ketone (TPCK) (Sigma-Aldrich) and 0.6% agarose (Oxoid Ltd., 
Hampshire, England). The cells were incubated for 60 h, fixed with 2 ml of 10% formalin 
for 15 min, and the agarose overlay was removed by washing with tap water. Plaques were 
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stained with 2 ml of 1% crystal violet/0.19% methanol for 15 min, rinsed with tap water, 
dried, counted, and the plaque forming units (PFU) were calculated.
Viral replication assay (VRA)
To increase the sensitivity of detecting viable virus, a modified tissue culture infectious dose 
endpoint 50% (TCID50) assay, the VRA, was developed.11 With the VRA, an aerosol sample 
containing a mixture of infectious and non-infectious virus is first incubated with MDCK 
cells to amplify the number of infectious virus present in the sample. Non-infectious virus is 
then washed from the cells, and the infected cells are lysed to release the amplified 
infectious viral particles which are subsequently detected by qPCR. We have previously 
shown that in the VRA, infectious virus in an aerosol sample was amplified 4.6 × 105 fold.11 
Briefly, prior to viral treatment, MDCK cells were trypsinized, washed and re-suspended in 
DMEM (Invitrogen) supplemented with 1% BSA (Invitrogen), 25 mM HEPES (Invitrogen), 
2 µg ml−1 L-10 tosylamido-2-phenylethyl chloromethyl ketone (TPCK) Trypsin (Sigma, St. 
Louis, MO), 0.2 units/ml penicillin, and 0.2 µg ml−1 streptomycin. Cells (200 µl) were 
plated in CoStar flat bottom 96-well plate 4 replicates) at a density of 5.0 × 104 cells per 
well (Corning) and incubated overnight. Plated cells were next treated with five 50 µl serial 
dilutions of each viral aerosol sample for 45 min. Infected cells were then washed with PBS, 
overlaid with 200 µl supplemented DMEM without agarose. Following 20 h of incubation, 
the cells were washed with PBS, 63 µl of Lysis/Binding Solution Concentrate was added to 
each well, and the plate was shaken at maximum speed for one minute on a Titer Plate 
Shaker. The 96-well plate containing the cellular lysate was stored at −20 °C until RNA 
extraction. Upon thawing, 77 µl of isopropanol was added to each sample well to complete 
the Lysis/Binding Solution preparation, and total RNA was extracted according to the 
manufacturer’s instructions. The final eluted total RNA volume was 32 µl. RNA was 
immediately transcribed into cDNA (40 µl) using High Capacity RNA to cDNA Master Mix.
Calculations
For each aerosol sampler in each experiment, the total viral particles collected (TVP), which 
represents both infectious and non-infectious virus, were determined by qPCR analysis of 
the collected sample. The total viral particles/liter of air sampled (TVP/L) was then 
calculated by dividing the TVP by the sampler flow rate and collection time. Similarly, the 
amount of infectious virus in each sampler was determined using VPA, and the number of 
PFU/liter of air sampled (PFU/L) was found by dividing the PFU by the sampler flow rate 
and collection time.
The aerosol particle concentration in the calm-air chamber and the amount of infectious and 
total virus particles in the nebulized solutions varied among the experiments, which 
introduced variations in the amount of infectious and total influenza particles collected by 
the samplers. To control for this, we normalized the total influenza particles and amount of 
infectious virus collected by the samplers as follows:
First, the aerosol particle concentration (total number of aerosol particles/liter of air) during 
the particle collection by each sampler during each experiment was determined based on the 
aerosol concentration data from the APS. Then, these concentrations for each sampler were 
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divided by the overall average aerosol concentration for all of the samplers during all of the 
experiments to give an aerosol concentration normalization factor, Naerosol.
Next, the concentrations of total influenza virus in the nebulizer solution for each 
experiment (as measured by qPCR) were divided by the overall average concentration of 
total virus for all of the experiments to give a total influenza concentration normalization 
factor, Ntotal virus.
In a similar fashion, the concentrations of infectious influenza virus in the nebulizer solution 
for each experiment (as measured by VPA) were divided by the overall average 
concentration of infectious virus to give an infectious influenza concentration normalization 
factor, Ninfectious virus.
Finally, these factors were used to calculate the normalized TVP, PFU, TVP/L and PFU/L 
collected by each sampler in each experiment:
Results
Assessment of airborne influenza virus collection by the NIOSH bioaerosol sampler
The NIOSH bioaerosol sampler (Fig. 1) was assessed for its ability to collect aerosolized 
influenza virus in a calm-air chamber (Fig. 2). The normalized TVP collected in the sampler 
tubes and filter increased with time from 1.3 × 106 TVP after 15 min to 2.2 × 106 TVP after 
30 min and 1.6 × 107 after 60 min (Table 1). The normalized TVP/liter of air for the NIOSH 
bioaerosol sampler was constant up to 30 min of collection, with 2.4 × 104 TVP/L found 
after 15 min of sampling and 2.1 × 104 TVP/L found after 30 min. After 60 min of 
sampling, the normalized TVP/L increased to 7.6 × 104 TVP/L (Table 1). For all 
experiments using the NIOSH bioaerosol samplers combined, the overall average collection 
was 3.5 × 104 TVP/L, which was comparable to the overall average of 2.6 × 104 TVP/L for 
the SKC BioSamplers.
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Assessment of viral infectivity following collection by the NIOSH sampler
Prolonged collection time has been shown to result in decreased viral recovery.10 Therefore, 
to determine whether the NIOSH sampler is able to collect infectious virus over an extended 
sampling period, collected samples were assayed for infective virus by the VPA. In Fig. 3, 
the number of PFU/liter of air that was detected in the NIOSH bioaerosol sampler is shown 
relative to the PFU/L found using the SKC BioSampler, which has been reported to preserve 
essentially all influenza virus infectivity during collection.1 The NIOSH bioaerosol sampler 
contained 34% of the PFU/L in the SKC BioSampler after 15 min, 28% after 30 min, and 
15% after 60 min. Infectious virus was found in all three size fractions of the NIOSH 
bioaerosol sampler.
Distribution of collected airborne influenza virus in different sampling stages
The particle sizes and concentrations of aerosols loaded in the calm-air chamber were 
monitored by an aerodynamic particle sizer (APS) for each experiment. A typical mass-
based aerosol particle size distribution in the calm-air chamber is shown in Fig. 4. The 
average distribution of collected infectious and total viral particles in the collection tubes 
and backup filter of the NIOSH bioaerosol samplers is shown in Table 2. Eighty-six percent 
of infectious particles (mean of the samples collected at three collection times) were 
contained in aerosols with diameters ≤ 4 µm. When the experimental results are averaged, 
the distribution of the infectious viral particles in the two stages and on the backup filter was 
similar regardless of collection times, though the distribution of the collected total viral 
particles appeared to vary with collection times. When compared to the 15 min collection 
time, the fraction of the total viral particles collected after 60 min decreased from 21% to 
3% in the Stage 1 tubes and increased from 37% to 63% on the backup filter (Table 2). 
However, within the same experiment, samplers with different collection times showed 
much less variability when comparing the distribution of infectious and total viral particles. 
This can be seen, for example, by comparing experiment #1 and experiment #2 where 
collection occurred for 30 and 60 min in each experiment, and with experiment #3 where 
collection occurred for 15 and 30 min (Table 3). These results indicate that the NIOSH 
bioaerosol samplers performed consistently over time when sampling the same aerosol 
cloud.
Effect of prolonged storage on viability
To determine whether prolonged storage of collected virus in the sampler’s collection tubes 
and filter, which may be unavoidable in some field studies, affected recovery and infectivity 
of the virus, a NIOSH bioaerosol sampler was placed at room temperature for 24 h before 
extracting the collected virus. The TVP detected from that stored sampler and the infectivity 
of the collected virus were compared with another sampler that was immediately processed 
after collection. The loss in infectivity of virus collected in the >4 µm, 1–4 µm, and <1 µm 
fractions was 74%, 57%, and 71%, respectively, resulting in a 60% overall loss in infectivity 
(data not shown). In contrast, the loss in TVP detected in the >4 µm, 1–4 µm, and <1 µm 
fractions was 15%, 17%, and 32%, respectively, resulting in a 20% overall loss in TVP (data 
not shown).
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Enhanced infectivity detection assay
The utility of the NIOSH sampler was extended by incorporating an enhanced infectivity 
detection methodology, the VRA. In the VRA, collected samples are first infected into 
MDCK cells and allowed to replicate in order to increase the ability to detect low levels of 
infectious virus in an aerosol sample. Calm-air chamber experiments that began with very 
low initial infectious virus (0.13–0.14%) were chosen for further analysis by the VPA as this 
may reflect the extent of infectivity expected in real-world environmental samples. Table 4 
shows that when the nebulizer was loaded with 2.8 × 107 TVP/ml, 6.4 × 102 infectious virus 
were detected by the VPA in the collected sample. With the VRA, 2.1 × 1010 matrix gene 
transcripts were detected from this sample. The viral suspension loaded into the nebulizer 
was then diluted 332-fold to 1.3 × 102 PFU/ml to determine whether the sensitivity of 
detecting infectious virus by the VRA exceeded that of the VPA. As shown in Table 4, no 
infectious virus was detected with the VPA. In contrast, 4.1 × 106 matrix gene transcripts 
were detected with the VRA.
Influenza virus concentration in the nebulizer
The initial and final concentration of virus in the nebulizer solution was measured during 
eight experiments. The average total virus concentration in the nebulizer fluid was 4.2 × 107 
viral particles/ml (SD 1.1 × 109) at the start of the experiments and 4.3 × 107 viral 
particles/ml (SD 4.1 × 107) at the end. The average concentration of infectious virus was 
initially 6.7 × 104 PFU/ml (SD 3.2 × 104) and was 6.5 × 104 PFU/ml (SD 2.6 × 104) at the 
end. Thus, the total viral particle number and the amount of infectious influenza virus in the 
nebulizer solution stayed the same over the course of the experiments.
Discussion
Concerns regarding the vulnerability of large populations to viruses that exacerbate 
respiratory infections such as pandemic strains of influenza A have prompted a number of 
studies into the modes of transmission.14–21 Aerosol samplers vary greatly in their efficiency 
to collect airborne particles, fractionate them by size, and maintain the infectivity of 
collected viruses. Recently, the efficiencies of four commercial air samplers were 
compared.1 In that study, collection of total viral particles by the SKC Bio-Sampler (which 
collects particles directly into a liquid media) was superior to 37 mm cassette samplers 
containing either a Teflon filter (74% recovery) or a gelatin filter (63% recovery), and the 
CCI sampler that contains a polyurethane foam filter (32% recovery). Of the four samplers 
tested, the SKC BioSampler maintained essentially 100% of the viability of the collected 
virus, whereas recoveries of viable virus from samplers with a gelatin filter, Teflon filter, or 
polyurethane filter were only 10%, 7%, and 22%, respectively. In our study, the ability of the 
NIOSH bioaerosol sampler to collect aerosolized particles containing influenza virus was 
essentially the same as that of the SKC BioSampler and was relatively constant over the 
collection times of 15, 30, and 60 min. The NIOSH bioaerosol sampler maintained an 
average of 26% of the virus infectivity compared to the SKC BioSampler. These results are 
higher than those reported1 for three other samplers, although it should be noted that a direct 
comparison cannot be made since Fabian et al.1 used a different viral strain, different 
aerosolization and collection media, and performed their experiments at 50 to 55% relative 
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humidity versus 20% for our experiments. The amount of infectious virus recovered from 
the NIOSH bioaerosol sampler is significantly lower than seen with the SKC BioSampler 
and does show a clear decline after 60 min of collection, suggesting that the dry collected 
virus gradually loses infectivity due to desiccation or degradation. This indicates that 
collection times should be kept to a minimum, and that the potential advantages of the 
NIOSH bioaerosol sampler need to be weighed against this drawback. Prolonged collection 
times with the SKC BioSampler result in significant loss of the collection media due to 
evaporation (26% loss of collection media in 15 min; data not shown) and thus should be 
avoided as well.
In this study, the infectivity of virus (assessed by the VPA) in the initial suspension used to 
generate the aerosolized particles was only 0.06–1.15% (average 0.53%) of the total viral 
particles. Viral stocks with similarly low (0.3–0.5%) infectivity were used by Fabian et al.1 
Conceivably the viability is actually much higher as viability assessed by the chicken 
embryo infectious dose endpoint 50% (CEID50) from the manufacturer (ATCC) is 10–50× 
higher. This discrepancy may simply reflect a lack of sensitivity of the VPA for determining 
infectivity or the initial infectivity of the stock may have degraded with storage, and 
emphasizes the need to increase the sensitivity of the infectivity assessments for future 
studies. To address this, we have combined the use of the NIOSH bioaerosol sampler with 
our VRA methodology which greatly facilitated our ability to detect infectious virus even 
when the initial infectivity in the nebulizer was only 0.13–0.14%. Dilution of the viral 
suspension loaded into the nebulizer from 3.8 × 104 PFU/ml to 1.3 × 102 PFU/ml (283-fold 
dilution), resulted in no PFU recovered in the collected samples, however, matrix gene 
transcripts arising from infectious virus in the samples were detected by the VRA.
A previous study1 on collection of infectious airborne virus has suggested that samplers 
containing collection medium can better preserve the infectivity of collected virus compared 
to those without collection medium. We found that the addition of supplemented HBSS to 
the collection tubes did not improve infectivity (data not shown), probably because the virus 
is deposited at the top of the tube and above the media rather than into the media. Adding 
more media, however, would negatively alter the aerodynamics of collection. In another 
approach, the top portion of the Stage 1 collection tubes were coated with 2% agar or 0.1% 
mucin, or supplemented HBSS-soaked electrets filters were inserted near the top. However, 
neither infectivity nor the total amount of recovered viral particles were increased over that 
found when uncoated tubes were used (data not shown).
The NIOSH bioaerosol sampler can be used for collection of bioaerosols in an outside 
environment although the presence of other microorganisms, dust, or pollen may alter the 
aerodynamics of fractionation or provide an additional vehicle hitchhiking mode of transport 
of transmission for the virus. In an earlier study, we co-aerosolized influenza A and 
Aspergillus versicolor fungal spores and found that the NIOSH bioaerosol sampler 
efficiently separated the two, but there was a shift in the overall deposition of virus to the 
Stage 1 collection tube and fewer viral particles were found on the backup filter.4 Humidity 
is also likely to influence recovery of infectious virus, as indicated in a study that showed the 
stability of influenza A is minimal at 50% relative humidity (RH), high at 60–80% RH, and 
maximal at 20–40% RH.22 A later study had similar results, finding that transmission of 
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influenza does not occur at 80% RH, is low at 50% RH, high at 65% RH, and maximal at 
20% and 35% RH.23 Moreover, the RH has been shown to affect the stability of other 
viruses including Semliki forest virus,24 HIV,25 and respiratory syncytial virus.26 For this 
study, we maintained the RH at 20%. Future work will include an investigation into the role 
of humidity on infectious recovery with the NIOSH sampler.
An important distinction between the NIOSH bioaerosol sampler and the SKC BioSampler 
is the ability to fractionate aerosols and identify which fractions contain infectious virus. 
Coughing, sneezing and talking generate airborne particles ranging in size from a few 
millimetres to <1 µm. Knowing whether infectious influenza is present in the respirable 
fraction would help provide a better assessment for risk of infection. Such information 
would dictate the personal protective equipment and guidelines for preventing personal 
exposure such as the type of particle mask or respirator to use, enable appropriate 
adjustments to air handling systems, and determine which personal protective measures need 
to be taken while conducting potentially aerosol-generating medical procedures during 
influenza outbreaks. Although the SKC BioSampler is significantly better at preserving viral 
infectivity and has a higher sample flow rate, the NIOSH bioaerosol sampler can be used 
with personal sampling pumps and worn as a personal sampler. Because it does not require 
aqueous buffers for collection of airborne virus, the collection time for the NIOSH 
bioaerosol sampler is not limited by water evaporation from the media, and the sampler is 
not sensitive to bouncing or tilting.
Conclusions
The use of the NIOSH bioaerosol sampler for the collection and detection of aerosols holds 
much promise. The collection efficiency of total aerosol viral particles is essentially the 
same as that of the SKC BioSampler. For the 15, 30, and 60 min collection times, on 
average, 26% of the aerosolized infectious virus collected with the NIOSH bioaerosol 
sampler remained infectious as compared with that collected over 15 min from the SKC 
BioSampler. Infectious virus was found in all three size fractions, although infectivity did 
decline with longer collection times. The demonstrated ability of the NIOSH bioaerosol 
sampler to collect infectious surrogate virus, influenza A, leads us to be cautiously 
optimistic for its potential use in the detection of other viruses and microorganisms.
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Environmental impact
Coughing, sneezing, and breathing generate a range of airborne particles that may contain 
infectious influenza virus, and respirable particles <10 µm are, arguably, the most 
problematic as they can remain airborne for hours. The use of the NIOSH aerosol 
sampler for investigation of environmental samples for influenza virus and potentially 
other viruses and microorganisms holds much promise. In this study, we show that the 
NIOSH air sampler can size fractionate collected aerosols and retain infectivity of 
aerosolized influenza to provide better assessments for risk of infection and precautionary 
guidelines for prevention.
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Fig. 1. Description of the NIOSH Bioaerosol Sampler
Ambient air is drawn into the sampler’s inlet at 3.5 L min−1 and initially enters the 1st stage 
15 ml polypropylene tube, where aerosol particles >4 µm are deposited on the wall of the 
tube. The air then enters the 2nd stage 1.5 ml polypropylene tube where 1 to 4 µm particles 
are deposited. After the air exits the 2nd stage, particles <1 µm are collected on a 37 mm 
PTFE filter.
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Fig. 2. Description of the Calm-air Chamber
Influenza virus is loaded into a nebulizer, mixed with dry air, and the aerosolized particles 
are dispersed into an air chamber. NIOSH bioaerosol samplers are placed into the bottom of 
the chamber and an SKC BioSampler is placed outside the chamber.
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Fig. 3. Infectious influenza virus detected in the NIOSH bioaerosol sampler
The amount of infectious influenza virus detected in each stage per liter of air collected is 
shown here relative to the amount detected in the SKC BioSampler. After 15, 30 and 60 min, 
the infectious virus/liter air found in the NIOSH bioaerosol sampler was 34%, 28% and 15% 
of that found in the SKC BioSampler.
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Fig. 4. Size distribution of influenza-laden aerosol particles in the calm-air chamber
The plot shows the estimated mass of aerosol particles vs. particle aerodynamic diameter for 
a typical experiment as measured by an Aerodynamic Particle Sizer. If the viral particles are 
evenly distributed in the nebulized droplets, the mass is proportional to the viral content. 
Over the range of the APS, the test aerosol containing HBSS and influenza virus had an 
average concentration of 1.33 × 106 particles/cm2, with a count median aerodynamic 
diameter of 0.8 µm and a geometric standard deviation of 1.26. The HBSS-only aerosol had 
Cao et al. Page 17
J Environ Monit. Author manuscript; available in PMC 2016 April 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
an average concentration of 1.20 × 106 particles/cm2, with a count median diameter of 0.7 
µm and a geometric standard deviation of 1.23.
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Table 1
Total influenza viral particles collected by NIOSH bioaerosol samplers and SKC BioSamplers in a calm-air 
chambera,b
Number of
NIOSH bioaerosol samplers Collection time (min) Normalized TVP Normalized TVP/L of air collected
2 15 1.3 × 106 (2.2 × 105) 2.4 × 104 (4.1 × 103)
16 30 2.2 × 106(1.4 × 106) 2.1 × 104 (1.3 × 104)
6 60 1.6 × 107(1.6 × 107) 7.6 × 104 (7.7 × 104)
All 24 samplers combined – – 3.5 × 104 (4.5 × 104)
Number of SKC BioSamplers Collection Time (min) Normalized TVP Normalized TVP/L of Air Collected
18 15 4.8 × 106 (5.2 × 106) 2.6 × 104 (2.8 × 104)
aAbbreviations: TVP, Total Viral Particles; Standard Deviation shown in parentheses.
bNumber of samplers per experiment varied from one to four.
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